Loading…
Loading…
Vanguard's broader healthcare portfolio charges less and yields more, but State Street's pharma-focused fund has delivered stronger recent gains despite higher volatility.
FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it.
CARMEL, Ind., and BURLINGTON, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Steve Hoerter, Chairman and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at, and participate in, the following upcoming investor conferences:
CARMEL, Ind. and BURLINGTON, Mass.
Jupiter Topco LLC acquired a new position in shares of MBX Biosciences, Inc. (NASDAQ: MBX) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 10,300 shares of the company's stock, valued at approximately $568,000. Several other institutional investors and hedge
Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable one-year clinical benefit
Q3 Revenues of $4.1 million and Controlled Net Loss MISSISSAUGA, ON / ACCESS Newswire / August 13, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and nine months of fiscal 2026 ended June 30, 2026 ("Q3" and "YTD"). Results for Q3 and YTD continue to demonstrate the results of the Company's continuing work to rebuild revenues back to profitability following two client setbacks in mid-2025, with revenue growth of 17% in Q3 compared to Q3 fiscal 2025.
MBX Biosciences, Inc. (NASDAQ: MBX - Get Free Report) shares hit a new 52-week high during mid-day trading on Thursday after Mizuho raised their price target on the stock from $57.00 to $91.00. Mizuho currently has an outperform rating on the stock. MBX Biosciences traded as high as $66.66 and last traded at $66.46, with a